ImmuPharma plc (LON:IMM – Get Free Report)’s stock price shot up 191.7% on Thursday . The stock traded as high as GBX 3.80 ($0.05) and last traded at GBX 3.50 ($0.04). 104,299,430 shares were traded during trading, an increase of 470% from the average session volume of 18,292,627 shares. The stock had previously closed at GBX 1.20 ($0.01).
ImmuPharma Price Performance
The company has a market cap of £15.30 million, a price-to-earnings ratio of -367.30 and a beta of 1.53. The business’s 50-day simple moving average is GBX 1.40 and its 200-day simple moving average is GBX 1.65.
ImmuPharma Company Profile
ImmuPharma plc, a biopharmaceutical company, discovers and develops peptide-based therapeutics. Its peptide-based therapeutics are used in the therapy areas of autoimmunity and inflammation, and anti-infectives. The company's lead product candidate is the Lupuzor, an autophagy immunomodulator, which is in Phase III clinical trial for the treatment of lupus, an autoimmune chronic inflammatory disease.
Read More
- Five stocks we like better than ImmuPharma
- Canada Bond Market Holiday: How to Invest and Trade
- 3 Natural Gas Stocks Set to Thrive in This Winter’s Freeze
- What Investors Need to Know to Beat the Market
- Bullish on Athleisure? Here’s Why Lululemon Stock Shines
- Manufacturing Stocks Investing
- MarketBeat Week in Review – 01/06 – 01/10
Receive News & Ratings for ImmuPharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ImmuPharma and related companies with MarketBeat.com's FREE daily email newsletter.
